Related Experiment Video
Updated: Jul 7, 2026
11:47
Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
Published on: January 22, 2017
A novel approach for treating cerebellar ataxias
Mario Manto1, Nordeyn Oulad Ben Taib
1FNRS-Neurologie, ULB Erasme, 808 Route de Lennik, 1070 Bruxelles, Belgium. mmanto@ulb.ac.be
Medical Hypotheses
|February 19, 2008
Summary
This study explores a novel neurostimulation therapy combining transcranial direct current stimulation (tDCS) and low-frequency repetitive stimulation (LFRSM1) to potentially improve cerebellar ataxia symptoms. The treatment aims to restore sensorimotor cortex excitability, offering a new management approach.
Area of Science:
- Neuroscience
- Neurology
- Rehabilitation Medicine
Background:
- Cerebellar ataxias are debilitating inherited or sporadic neurological disorders characterized by motor deficits like dysmetria and gait ataxia.
- Current treatments for degenerative cerebellar ataxias are limited, with significant deficits in sensorimotor cortex excitability observed in patients.
- Reduced cortical excitability is linked to learning impairments, highlighting a critical need for therapeutic interventions.
Purpose of the Study:
- To investigate the efficacy of a novel combined neurostimulation therapy for improving cerebellar ataxia.
- To test the hypothesis that transcranial direct current stimulation (tDCS) and low-frequency repetitive stimulation of the motor cortex (LFRSM1) can restore sensorimotor cortex excitability.
- To evaluate a new, feasible, and safe symptomatic treatment approach for cerebellar ataxia patients.
Main Methods:
- A three-step procedure involving clinical and quantitative assessments of patients with cerebellar disorders.
- Delivery of transcranial direct current stimulation (tDCS) and low-frequency repetitive stimulation of the motor cortex (LFRSM1) in a cross-over, sham-controlled design.
- Application of peripheral nerve stimulation to enhance sensorimotor cortex sensitization.
Main Results:
- Experimental data in animal models show tDCS and LFRSM1 restore motor cortex excitability and adaptive capabilities.
- The proposed combined neurostimulation therapy aims to reinstate the motor cortex's ability to adapt to peripheral stimulation.
- The study hypothesizes that this combined approach can lead to symptomatic improvement in human cerebellar ataxias.
Conclusions:
- A successful combined neurostimulation treatment would represent a significant advancement in managing cerebellar ataxias.
- This novel therapy is proposed as a safe, feasible, and readily available option compared to developing stem cell or gene therapies.
- The approach holds promise for providing symptomatic relief and improving the quality of life for individuals with cerebellar ataxia.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...